BioCentury | Apr 22, 2010
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Aneurysm Cyclin M2 (CNNM2); retinoblastoma binding protein...
...susceptibility to intracranial aneurysms. In cohorts from Europe and Japan, rs11661542, near RBBP8; rs12413409, in CNNM2...
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Ophthalmic disease Ophthalmic; dental Cyclin M4 (CNNM4) Genomewide haplotype analysis identified mutations in CNNM4 that could be targeted to help...
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Ophthalmic disease Ophthalmic; dental Cyclin M4 (CNNM4) A genetic study in humans suggests that mutations in CNNM4 may be useful...
Items per page:
1 - 3 of 3